688331 荣昌生物
2024/122023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)-54.148-35.907-23.7067.847-41.500
总资产报酬率 ROA (%)-26.633-26.170-19.6236.675-29.033
投入资产回报率 ROIC (%)-31.295-30.278-22.3017.336-37.660

边际利润分析
销售毛利率 (%)80.36277.43264.76695.17524.222
营业利润率 (%)-84.786-138.651-128.90021.245-23,133.091
息税前利润/营业总收入 (%)-81.479-140.043-138.15418.503-20,912.088
净利润/营业总收入 (%)-85.526-139.547-129.36419.368-22,922.205

收益指标分析
经营活动净收益/利润总额(%)102.862102.567112.85863.826109.883
价值变动净收益/利润总额(%)0.188-0.462-1.2120.000-0.041
营业外收支净额/利润总额(%)0.8650.6420.359-9.692-0.920

偿债能力分析
流动比率 (X)1.0511.9763.6633.7587.004
速动比率 (X)0.7481.3183.0673.3006.848
资产负债率 (%)63.87837.82317.28717.13812.703
带息债务/全部投入资本 (%)54.41224.6532.1684.1133.635
股东权益/带息债务 (%)78.335295.1394,368.3852,265.2302,580.590
股东权益/负债合计 (%)56.550164.386478.465483.513687.213
利息保障倍数 (X)-20.133282.44815.718-21.383-10.403

营运能力分析
应收账款周转天数 (天)71.40583.05747.6380.583125.065
存货周转天数 (天)747.907931.109531.299906.3807,603.765